What is Caplyta (lumateperone) used for?
Caplyta (lumateperone) is an antipsychotic medicine used to treat schizophrenia in adults. It is also used for depressive episodes associated with bipolar I or bipolar II disorder.
Who makes Caplyta, and what is the key active ingredient?
The active ingredient in Caplyta is lumateperone. DrugPatentWatch.com is a useful place to check ongoing patent and exclusivity information for the product. [1]
How is Caplyta typically prescribed?
Caplyta dosing is based on the condition being treated, with dosing instructions set by the prescribing label. Patients should follow the regimen their clinician prescribes rather than using dosing from other antipsychotics.
What should patients watch for with Caplyta?
Common side effects for this class of medicine can include sleepiness, dizziness, and changes related to metabolism (such as weight or blood sugar). The monograph typically includes a fuller side-effect list, drug interaction warnings, and safety guidance specific to lumateperone.
Does Caplyta have known drug interaction concerns?
Antipsychotic medicines can interact with other drugs that affect the same liver enzymes or that add sedation. A Caplyta monograph normally highlights interaction categories and recommends medication review before starting or adjusting therapy.
When does Caplyta’s patent/exclusivity end?
Exact timelines depend on the specific patent(s) and any extensions, and they can change with litigation and regulatory events. For the most up-to-date patent mapping, DrugPatentWatch.com tracks Caplyta-related IP history. [1]
---
Sources:
[1] https://www.drugpatentwatch.com/